Abstract:Levofloxacin is the L-form of the fluoroquinolone antibacterial agent, ofloxacin. In in vitro studies, levofloxacin demonstrated a broad range of activity against Gram-positive and -negative organisms and anaerobes. The drug is more active against Gram-positive organisms than ciprofloxacin, but less active than newer fluoroquinolones such as gatifloxacin. Its activity against Streptococcus pneumoniae is unaffected by the presence of penicillin resistance. In several randomised controlled trails, 5 to 14 days' treatment with intravenous and/or oral levofloxacin proved an effective therapy for upper and lower respiratory tract infections. In patients with mild to severe community-acquired pneumonia (CAP), intravenous and/or oral levofloxacin 500mg once or twice daily was as effective as intravenous and/or oral gatifloxacin, clarithromycin, azithromycin or amoxicillin/clavulanic acid. Overall, clinical response rates with levofloxacin ranged from 86 to 95% versus 88 to 96% with comparator agents; bacteriological response rates were 88 to 95% and 86 to 98%, respectively. Sequential (intravenous +/- oral switch) therapy with levofloxacin 750mg once daily was as effective as intravenous imipenem/cilastatin (+/- oral switch to ciprofloxacin) in patients with severe nosocomial pneumonia. Generally, oral levofloxacin 250 or 500mg once daily was at least as effective as oral cefaclor, cefuroxime axetil, clarithromycin or moxifloxacin in patients with acute exacerbations of chronic bronchitis as assessed by either clinical or bacteriological response rates. This approach also provided similar efficacy to amoxicillin/ clavulanic acid or clarithromycin in patients with acute sinusitis. Sequential therapy with levofloxacin 500mg twice daily for 7 to 14 days' was as effective as intravenous imipenem/cilastatin in patients with suspected bacteraemia. Oral levofloxacin 500mg once daily for 7 to 10 days was also an effective treatment in patients with uncomplicated skin and skin structure infections, and in those with complicated urinary tract infections. A higher dosage of sequential levofloxacin 750mg once daily proved as effective as intravenous ticarcillin/clavulanic acid (+/- oral switch to amoxicillin/clavulanic acid) in the treatment of complicated skin and skin structure infections. Pharmacoeconomic studies suggest that levofloxacin may be cost-saving in comparison to conventional therapies. Conclusions: Levofloxacin continues to demonstrate good clinical efficacy in the treatment of a range of infections, including those in which S. pneumoniae is a potential pathogen. Importantly, it has efficacy in CAP similar to that of gatifloxacin and at least as good as that of the third generation cephalosporins. Extensive clinical data confirm the good tolerability profile of this agent without the phototoxicity, hepatic and cardiac events evident with some of the other newer fluoroquinolone agents. Levofloxacin therefore offers a unique combination of documented efficacy and tolerability, and provides an important option for the treatment of bacterial infections.

Orbifloxacin: A Review of Properties, Its Antibacterial Activities, Pharmacokinetic/Pharmacodynamic Characteristics, Therapeutic Use, and Analytical Methods

Levofloxacin in veterinary medicine: a literature review

Enrofloxacin—The Ruthless Killer of Eukaryotic Cells or the Last Hope in the Fight against Bacterial Infections?

A Review of Levofloxacin for the Treatment of Bacterial Infections

Levofloxacin: a therapeutic review

Antibacterial and Pharmacological Evaluation of Fluoroquinolones: A Chemoinformatics Approach

Levofloxacin: an updated review of its use in the treatment of bacterial infections

Levofloxacin and trovafloxacin: the next generation of fluoroquinolones?

In vitro potency and efficacy favor later generation fluoroquinolones for treatment of canine and feline Escherichia coli uropathogens in the United States

A pharmacodynamic investigation to assess the synergism of orbifloxacin and propyl gallate against Escherichia coli

Method Development and Stability Indicating Studies of Marbofloxacin a Promising Antibiotic for Veterinary Use

Antibacterial Mechanisms and Clinical Impact of Sitafloxacin

Levofloxacin, a Second‐Generation Fluoroquinolone

Levofloxacin for the treatment of respiratory tract infections

Expanded activity and utility of the new fluoroquinolones: a review

Antibacterial Activity, Pharmacokinetics and Therapeutic Efficacy in Poultry of a New Cephalosporin-fluoroquinolone (CQ) Molecule

In Vivo Pharmacokinetic and Pharmacodynamic Profiles of Antofloxacin Against Klebsiella Pneumoniae in a Neutropenic Murine Lung Infection Model.

In Vivo Bioluminescent Monitoring of Therapeutic Efficacy and Pharmacodynamic Target Assessment of Antofloxacin Against Escherichia Coli in a Neutropenic Murine Thigh Infection Model.

Profile of a Novel Anionic Fluoroquinolone-Delafloxacin

[Antibacterial activity and pharmacological features of fluoroquinolones and considerations on their use in a nosocomial setting]

Clinical and pharmacokinetic drug evaluation of delafloxacin for the treatment of acute bacterial skin and skin structure infections